Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KALA Stock Forecast 2025-2026
$3.18
Current Price
$21.29M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KALA Price Targets
+371.7%
To High Target of $15.00
+371.7%
To Median Target of $15.00
+371.7%
To Low Target of $15.00
KALA Price Momentum
-3.3%
1 Week Change
-47.4%
1 Month Change
-49.5%
1 Year Change
-54.2%
Year-to-Date Change
-71.6%
From 52W High of $11.20
+8.9%
From 52W Low of $2.92
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Kala Pharma (KALA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on KALA and similar high-potential opportunities.
Latest KALA Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, KALA has a bullish consensus with a median price target of $15.00 (ranging from $15.00 to $15.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $3.18, the median forecast implies a 371.7% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 371.7% upside. Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 371.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KALA Analyst Ratings
2
Buy
0
Hold
0
Sell
KALA Price Target Range
Low
$15.00
Average
$15.00
High
$15.00
Current: $3.18
Latest KALA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KALA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 4, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $15.00 |
| Feb 13, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $15.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $15.00 |
| Aug 19, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $15.00 |
| May 17, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $18.00 |
| Apr 2, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $21.00 |
| Apr 1, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $15.00 |
| Nov 17, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $22.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $24.00 |
| May 10, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $24.00 |
| May 1, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $22.00 |
| Apr 12, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $22.00 |
| Mar 27, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $20.00 |
| Mar 6, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $20.00 |
| Aug 15, 2022 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $2.50 |
| May 24, 2022 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $4.00 |
| May 17, 2022 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $5.00 |
| Mar 30, 2022 | JP Morgan | Underweight | Downgrade | $0.00 | |
| Mar 30, 2022 | Northland Capital Markets | Tim Chiang | Outperform | Maintains | $4.00 |
| Mar 30, 2022 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $6.00 |
Kala Pharmaceuticals, Inc. (KALA) Competitors
The following stocks are similar to Kala Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kala Pharmaceuticals, Inc. (KALA) Financial Data
Kala Pharmaceuticals, Inc. has a market capitalization of $21.29M with a P/E ratio of 11.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -388.3%.
Valuation Metrics
Market Cap
$21.29M
Enterprise Value
$1.59M
P/E Ratio
11.4x
PEG Ratio
-0.5x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+249.4%
Current Ratio
3.1x
Debt/Equity
261.5x
ROE
-388.3%
ROA
-45.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Kala Pharmaceuticals, Inc. (KALA) Business Model
About Kala Pharmaceuticals, Inc.
What They Do
Develops therapies for eye diseases.
Business Model
The company utilizes its proprietary AMPPLIFY™ drug delivery technology to enhance drug penetration in the eye, targeting unmet needs in ophthalmology. It generates revenue through the commercialization of its products, such as EYSUVIS and INVELTYS, which treat conditions like dry eye disease and post-surgical inflammation.
Additional Information
Kala Pharmaceuticals is headquartered in Massachusetts and aims to advance patient care in optometry and ophthalmology. Its focus on innovative therapies positions it strategically within the pharmaceutical and healthcare markets.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
38
CEO
Mr. Todd Bazemore
Country
United States
IPO Year
2017
Website
www.kalarx.comKala Pharmaceuticals, Inc. (KALA) Latest News & Analysis
Latest News
Quick Summary
KALA Bio, Inc. announced the resignation of CEO Mark Iwicki, with Todd Bazemore appointed as interim CEO. Iwicki remains Chair of the Board. Bazemore has been with KALA since 2017.
Why It Matters
Leadership changes can impact company direction and investor confidence. The appointment of an interim CEO may signal uncertainty or transition, influencing stock performance and strategic decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
KALA BIO Announces $10,750,000 Private Placement
3 months ago
Quick Summary
KALA BIO, Inc. has secured a private placement agreement with institutional investors, raising approximately $10.75 million through the sale of common stock and Series I Convertible Preferred Stock.
Why It Matters
KALA BIO's $10.75 million private placement signals financial backing for its development efforts, potentially impacting stock liquidity and future growth prospects in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
KALA BIO (KALA) shows a hammer chart pattern, suggesting support after recent losses, alongside rising earnings estimate revisions, indicating a potential trend reversal.
Why It Matters
KALA's hammer pattern signals potential support and trend reversal, alongside rising earnings estimates, suggesting a favorable outlook for the stock's performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
KALA BIO, Inc. (NASDAQ:KALA) will present at the Piper Sandler Healthcare Conference on December 4, 2024, at 11:30 a.m. ET, with management available for one-on-one meetings.
Why It Matters
KALA BIO's presentation at a prominent healthcare conference highlights its commitment to innovation in eye disease therapies, potentially influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
KALA Bio (KALA) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating improved earnings prospects and potential for stock price increase.
Why It Matters
KALA BIO's upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving the stock price up in the near term.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
KALA Bio (KALA) shows signs of support with a hammer chart pattern, and Wall Street analysts have revised earnings estimates higher, indicating potential for a near-term turnaround.
Why It Matters
KALA's hammer chart suggests a potential price reversal, while upgraded earnings estimates from analysts indicate improving fundamentals, signaling a possible buying opportunity.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About KALA Stock
What is Kala Pharmaceuticals, Inc.'s (KALA) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Kala Pharmaceuticals, Inc. (KALA) has a median price target of $15.00. The highest price target is $15.00 and the lowest is $15.00.
Is KALA stock a good investment in 2025?
According to current analyst ratings, KALA has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KALA stock?
Wall Street analysts predict KALA stock could reach $15.00 in the next 12 months. This represents a 371.7% increase from the current price of $3.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kala Pharmaceuticals, Inc.'s business model?
The company utilizes its proprietary AMPPLIFY™ drug delivery technology to enhance drug penetration in the eye, targeting unmet needs in ophthalmology. It generates revenue through the commercialization of its products, such as EYSUVIS and INVELTYS, which treat conditions like dry eye disease and post-surgical inflammation.
What is the highest forecasted price for KALA Kala Pharmaceuticals, Inc.?
The highest price target for KALA is $15.00 from Yi Chen at HC Wainwright & Co., which represents a 371.7% increase from the current price of $3.18.
What is the lowest forecasted price for KALA Kala Pharmaceuticals, Inc.?
The lowest price target for KALA is $15.00 from Yi Chen at HC Wainwright & Co., which represents a 371.7% increase from the current price of $3.18.
What is the overall KALA consensus from analysts for Kala Pharmaceuticals, Inc.?
The overall analyst consensus for KALA is bullish. Out of 9 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are KALA stock price projections?
Stock price projections, including those for Kala Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 6:20 PM UTC